HDAC9 and colorectal carcinoma: Aside from pan-HDAC inhibitors, selective HDAC inhibitors targeting other HDAC isoforms were investigated in clinical trials in patients with CRC in advanced stages of the disease, but mostly in combination with other therapeutics.